Human mammaglobin in breast cancer: A brief review of its clinical utility

Indian Journal of Medical Research

Volumn 139, Issue MAY, 2014, Pages 675-685

  Al Joudi, Fawwaz Shakir ^a  

^a Perak State Government   (Malaysia)

Author keywords

Breast cancer; Diagnosis; Immunotherapy; Mammaglobin; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 20; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HLA A ANTIGEN; KI 67 ANTIGEN; MAMMAGLOBIN; MASPIN; MESSENGER RNA; MUCIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; SURVIVIN; UROKINASE; MAMMAGLOBIN A; TUMOR MARKER; UTEROGLOBIN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NORTHERN BLOTTING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING; BIOSYNTHESIS; BLOOD; BREAST NEOPLASMS; DIAGNOSTIC USE; FEMALE; GENETICS; LYMPH NODE METASTASIS; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMAGLOBIN A; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UTEROGLOBIN;

EID: 84903776169     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Smith JA, Andreopoulou E. An overview of the status of imaging screening technology for breast cancer. Ann Oncol 2004; 15 (Suppl 1): I18-26.
2. Szoke J, Udvarhelyi N. [Modern pathologic diagnostics in breast cancer]. Orv Hetil 2012; 153: 22-30.
3. Duffy MJ. Serum tumor markers in breast cancer: are they ofclinical value? Clin Chem 2006; 52: 345-51.
4. Marić P, Ozretić P, Levanat S, Oresković S, Antunac K, Beketić-Oresković L. Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol 2011; 35: 241-7.
5. Al-Joudi FS, Iskandar ZA, Hasnan J, Rusli J, Kamal Y, ImranAK, et al. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med J 2007; 48: 607-14.
6. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, ArrigoniG, et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol 2001; 12: 1693-8.
7. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Oestrogenreceptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29-35.
8. MolinaR, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol 2005; 26: 281-93.
9. O'Brien N, O'Donovan N, Foley D, Hill AD, McDermottE, O'Higgins N, et al. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues. Tumour Biol 2007; 28: 312-7.
10. Bernstein JL, Godbold JH, Raptis G, Watson MA, LevinsonB, Aaronson SA, et al. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005; 11: 6528-35.
11. Leong AS, Zhuang Z. The changing role of pathology inbreast cancer diagnosis and treatment. Pathobiology 2011; 78: 99-114.
12. Jensen EV, Jordan VC. The oestrogen receptor: a model formolecular medicine. Clin Cancer Res 2003; 9: 1980-9.
13. Watson MA, Fleming TP. Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 1994; 54: 4598-602.
14. El-Sharkawy SL, El-Aal WE, El-Shaer MA, Abbas NF, Youssef MF. Mammaglobin: a novel tumor marker for breast cancer. Turkish J Cancer 2007; 37: 89-97.
15. O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, et al. Mammaglobin a: a promising marker for breast cancer. Clin Chem 2002; 48: 1362-4.
16. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004; 22: 691-8.
17. Zafrakas M, Petschke B, Donner A, Fritzsche F, KristiansenG, Knüchel R, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006; 6: 88.
18. Zehentner BK, Carter D. Mammaglobin: a candidate diagnosticmarker for breast cancer. Clin Biochem 2004; 37: 249-57.
19. Grünewald K, Haun M, Fiegl M, Urbanek M, Müller-HolznerE, Massoner A, et al. Mammaglobin expression in gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction. Lab Invest 2002; 82: 1147-53.
20. Onuma K, Dabbs DJ, Bhargava R. Mammaglobin expressionin the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol 2008; 27: 418-25.
21. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, YatabeY. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007; 20: 208-14.
22. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, CalzaS, et al. Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol 2007; 105: 578-85.
23. Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, RossiE, et al. Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer 2008; 18: 1090-6.
24. Bonadio AG, Ferro P, Moroni M, Gorji N, Giannico A, Dessanti P, et al. Poorly differentiated breast carcinoma with an abundant myoepithelial component: morphologic and immunohistochemical features and mammaglobin gene expression. Pathologica 2003; 95: 209-13.
25. Klug J, Beier HM, Bernard A, Chilton BS, Fleming TP, LehrerRI, et al. Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Ann NY Acad Sci 2000; 923: 348-54.
26. Ni J, Kalff-Suske M, Gentz R, Schageman J, Beato M, KlugJ. All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann N Y Acad Sci 2000; 923: 25-42.
27. Watson MA, Fleming TP, Mammaglobin, a mammary-specificmember of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56: 860-5.
28. Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 2002; 41: 6714-22.
29. Colpitts TL, Billing-Medel P, Friedman P, Granados EN, Hayden M, Hodges S, et al. Mammaglobin is found in breast tissue as a complex with BU101. Biochemistry 2001; 40: 11048-59.
30. Becker RM, Darrow C, Zimonjic DB, Popescu NC, WatsonMA, Fleming TP. Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics 1998; 54: 70-8.
31. O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, et al. Mammaglobin a in breast cancer: existence of multiple molecular forms. Int J Cancer 2005; 114: 623-7.
32. Watson MA, Darrow C, Zimonjic DB, Popescu NC, FlemingTP. Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome11q13. Oncogene 1998; 16: 817-24.
33. Hesselbrock DR, Kurpios N, Hassell JA, Watson MA, Fleming TP. PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin. Breast Cancer Res Treat 2005; 89: 289-96.
34. Sjödin A, Ljuslinder I, Henriksson R, Hedman H. Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation. Anticancer Res 2008; 28: 1493-8.
35. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersioJ, Jensen R, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59: 3028-31.
36. Pattabiraman N, Matthews JH, Ward KB, Mantile-Selvaggi G, Miele L, Mukherjee AB. Crystal structure analysis of recombinant human uteroglobin and molecular modeling of ligand binding. Ann N Y Acad Sci 2000; 923: 113-27.
37. Al-Joudi FS, Kaid FA, Ishak I, Mohamed N, Osman K, AliasIZ. Expression of human mammaglobin and clinicopathologic correlations in breast cancer: findings in Malaysia. Indian J Pathol Microbiol 2011; 54: 284-9.
38. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 2007; 22: 1221-30.
39. Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J, Jiang J, et al. Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn 2001; 6: 79-91.
40. Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, Hiller-Hitchcock T, et al. Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol 1999; 189: 28-33.
41. Raica M, Cîmpean AM, Meche A, Alexa A, Suciu C, MureşanA. Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis. Rom J Morphol Embryol 2009; 50: 341-7.
42. Rehman F, Nagi AH, Hussain M. Immunohistochemical expression and correlation of mammaglobin with the grading system of breast carcinoma. Indian J Pathol Microbiol 2010; 53: 619-23.
43. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Giannico A, Gorji N, et al. Relationship between human mammaglobin mRNA expression in breast cancer tissue and clinico-pathologic features of the tumors. J Exp Clin Cancer Res 2006; 25: 65-72.
44. Silva AL, Tomé MJ, Correia AE, Passos-Coelho JL. Humanmammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products. Ann Oncol 2002; 13: 422-9.
45. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, ParkBH, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011; 135: 587-91.
46. Leung K. VivoTag-S 680-anti-human mammaglobin-A monoclonal antibody. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-13.
47. Mikhitarian K, Martin RH, Ruppel MB, Gillanders WE, HodaR, Schutte del H, et al. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer 2008; 8: 55.
48. El-Attar NI, Gaefar HA. Plasma mammaglobin messengerRNA in breast cancer patients as an addition to serum tumor. Egypt J Immunol 2007; 14: 111-21.
49. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007; 127: 103-13.
50. Fleming TP, Watson MA. Mammaglobin, a breast-specificgene, and its utility as a marker for breast cancer. Ann N Y Acad Sci 2000; 923: 78-89.
51. Fanger GR, Houghton RL, Retter MW, Hendrickson RC, Babcook J, Dillon DC, et al. Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol 2002; 23: 212-21.
52. Suchy B, Austrup F, Driesel G, Eder C, Kusiak I, UciechowskiP, et al. Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett 2000; 158: 171-8.
53. Zach O, Kasparu H, Krieger O, Hehenwarter W, GirschikofskyM, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17: 2015-9.
54. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D. Mammaglobin as a marker for the detection of tumor cells in the peripheral blood of breast cancer patients. Ann N Y Acad Sci 2000; 923: 343-5.
55. Li G, Zhang J, Jin K, He K, Wang H, Lu H, et al. Human mammaglobin: a superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med 2011; 5: 249-60.
56. Han JH, Kang Y, Shin HC, Kim HS, Kang YM, Kim YB, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med 2003; 127: 1330-4.
57. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki MondenM. Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat 1999; 58: 137-40.
58. Ghaffari SR, Sabokbar T, Tahmasebi S, Dastan J, ShorakaeS, Moradi A, et al. Combining mammaglobin and carcinoembryonic mRNA markers for early detection of micrometastases from breast cancers--a molecular study of 59 patients. Asian Pac J Cancer Prev 2006; 7: 396-8.
59. Janku F, Kleibl Z, Novotny J, Tesarova P, Petruzelka L, MatousB. Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma 2004; 51: 204-8.
60. Liu N, Zhang W, Shao Y. [Mammaglobin mRNA measurementin the detection of micrometastasis in peripheral blood of breast cancer patients]. Zhonghua Zhong Liu Za Zhi 2001; 23: 317-9.
61. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006; 39: 879-87.
62. Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, FolliS, et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol 2006; 17: 424-8.
63. Ballestrero A, Garuti A, Bertolotto M, Rocco I, Boy D, NencioniA, et al. Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer 2005; 92: 1948-52.
64. Roncella S, Ferro P, Bacigalupo B, Pronzato P, Tognoni A, Falco E, et al. Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. J Exp Clin Cancer Res 2005; 24: 265-71.
65. Zehentner BK, Dillon DC, Jiang Y, Xu J, Bennington A, MoleshDA, et al. Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 2002; 48: 1225-31.
66. Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, FalcoE, Fontana V, et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. Anticancer Res 2010; 30: 2377-82.
67. Verbanac KM, Min CJ, Mannie AE, Lu J, O'Brien KF, Rosman M, et al; ElU/AAMC Sentinel Node Study Group. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases. Ann Surg Oncol 2010; 17 (Suppl 3): 368-77.
68. Dono M, Ferro P, Benedetti L, Capellini C, Moroni M, Dessanti P, et al. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. J Neurooncol 2009; 91: 295-8.
69. Dono M, Ferro P, Franceschini MC, Dessanti P, Bacigalupo B, Cibei E, et al. Human mammaglobin transcript amplification for differential diagnosis in a breast cancer metastatic to dura mater. Anticancer Res 2011; 31: 1061-4.
70. Chia SY, Thike AA, Cheok PY, Tan PH. Utility of mammaglobinand gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast 2010; 19: 355-9.
71. Ciampa A, Fanger G, Khan A, Rock KL, Xu B. Mammaglobinand CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer 2004; 102: 368-72.
72. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Pronzato P, Franceschini MC, et al. Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn Mol Pathol 2008; 17: 28-33.
73. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, DessantiP, Sivori M, et al. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol 2010; 19: 92-8.
74. Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol 2009; 2: 384-9.
75. Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, ChhiengDC. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol 2009; 37: 475-8.
76. Fernandez-Flores A. Mammaglobin immunostaining in thedifferential diagnosis between cutaneous apocrine carcinoma and cutaneous metastasis from breast carcinoma. Cesk Patol 2009; 45: 108-12.
77. Kanner WA, Galgano MT, Stoler MH, Mills SE, AtkinsKA. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin. Int J Gynecol Pathol 2008; 27: 491-5.
78. Aihara T, Fujiwara Y, Miyake Okami J, Okada Iwao K, et al. Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett 2000; 150: 79-84.
79. Bregni M, Fleischhauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, et al. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplant 2006; 37: 311-5.
80. Fiegl M, Haun M, Massoner A, Krugmann J, Müller-HolznerE, Hack R, et al. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/ mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 2004; 22: 474-83.
81. Gargano G, Agnese V, Calò V, Corsale S, Augello C, BrunoL, et al. Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006; 17 (Suppl 7): vii41-5.
82. Cerveira N, Torres L, Rocha P, Bizarro S, Pereira D, Abreu J, et al. Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. Int J Cancer 2004; 108: 592-5.
83. Reyes C, Gomez-Fernández C, Nadji M. Metaplastic andmedullary mammary carcinomas do not express mammaglobin. Am J Clin Pathol 2012; 137: 747-52.
84. Lin YC, Wu Chou YH, Liao IC, Cheng AJ. The expression ofmammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers. Cancer Lett 2003; 191: 93-9.
85. Ferrucci PF, Rabascio C, Gigli F, Corsini C, GiordanoG, Bertolini F, Martinelli G. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 2007; 30: 955-62.
86. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006; 43: 325-47.
87. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998; 58: 4581-4.
88. Benoy IH, Elst H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, et al. Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med 2006; 44: 1082-7.
89. Dell'Orto P, Biasi MO, Del Curto B, Zurrida S, Galimberti V, Viale G. Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. Breast Cancer Res Treat 2006; 98: 185-90.
90. Kataoka A, Mori M, Sadanaga N, Ueo H, Tsuji K, Rai Y, et al. RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol 2000; 16: 1147-52.
91. Marchetti A, Buttitta F, Bertacca G, Zavaglia K, BevilacquaG, Angelucci D, et al. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. J Pathol 2001; 195: 186-90.
92. Ouellette RJ, Richard D, Maïcas E. RT-PCR for mammaglobingenes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol 2004; 121: 637-43.
93. Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 2010; 25: 59-68.
94. Julian TB, Blumencranz P, Deck K, Whitworth P, BerryDA, Berry SM, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol 2008; 26: 3338-45.
95. Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, HeikkiläR, Kvaløy JT, et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010; 10: 378-84.
96. Berger J, Mueller-Holzner E, Fiegl H, Marth C, Daxenbichler G. Evaluation of three mRNA markers for the detection of lymph node metastases. Anticancer Res 2006; 26: 3855-60.
97. Gimbergues P, Dauplat MM, Cayre A, Durando X, le BouedecG, Finat-Duclos F, et al. Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category. Eur J Surg Oncol 2007; 33: 16-22.
98. Grünewald K, Haun M, Urbanek M, Fiegl M, Müller-HolznerE, Gunsilius E, et al. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest 2000; 80: 1071-7.
99. Shen C, Hu L, Xia Li Y. The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem 2009; 42: 194-200.
100. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011; 57: 421-30.
101. Guan XF, Hamedani MK, Adeyinka A, Walker C, KempA, Murphy LC, et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 2003; 21: 245-50.
102. Ceballos MP, Zumoffen C, Massa E, Cipulli G, Funes CC, GilAB, et al. Detection of mammaglogin A in blood from breast cancer patients, before and after treatment, using a one-tube nested PCR protocol. Association with the absence of tumor estrogen receptors. Clin Biochem 2011; 44: 1429-33.
103. Lopez-Bonet E, Pérez-Martínez MC, Martin-Castillo B, Alonso-Ruano M, Tuca F, Oliveras-Ferraros C, et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. Breast Cancer Res Treat 2011; 126: 241-5.
104. Rollins-Raval M, Chivukula M, Tseng GC, Jukic D, DabbsDJ. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature. Arch Pathol Lab Med 2011; 135: 975-83.
105. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-8.
106. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
107. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008; 14: 2593-600.
108. Tjensvoll K, Gilje B, Oltedal S, Shammas VF, Kvaløy JT, Heikkilä R, et al. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow. Breast Cancer Res Treat 2009; 116: 329-38.
109. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D. Prognosticvalue of tumour cell detection in peripheral blood of breast cancer patients. Acta Med Austriaca 2002; 59 (Suppl): 32-4.
110. Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, et al. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clin Cancer Res 2004; 10: 6039-46.
111. Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, LiawIC, et al. Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci 2003; 94: 99-102.
112. Marques AR, Teixeira E, Diamond J, Correia H, Santos S, Neto et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 2009; 114: 223-32.
113. Nunez-Villar MJ, Martinez-Arribas F, Pollan M, LucasAR, Sanchez J, Tejerina A, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 2003; 5: R 65-70.
114. Bitisik O, Saip P, Saglam S, Derin D, Dalay N. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2010; 9: 97-106.
115. Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, ScanniA, et al. Detection of micrometastatic cells in breast cancer by RT-PCR for the mammaglobin gene. Cancer Detect Prev 2002; 26: 60-3.
116. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, et al. [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi 2006; 28: 766-9.
117. Bharat A, Benshoff N, Fleming TP, Dietz JR, Gillanders WE, Mohanakumar T. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HlA-class-I tetramers. Breast Cancer Res Treat 2008; 110: 453-63.
118. Ilias Basha H, Tiriveedhi V, Fleming TP, Gillanders WE, Mohanakumar T. Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from ammaglobin-A expressed on human breast cancers. Breast Cancer Res Treat 2011; 127: 81-9.
119. Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, GoedegebuurePS. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Surgery 2003; 133: 74-80.
120. Zuo L, Li L, Wang Q, Fleming TP, You S. Mammaglobin asa potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009; 23: 9-8.
121. Jaramillo A, Majumder K, Manna PP, Fleming TP, DohertyG, Dipersio JF, et al. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer 2002; 102: 499-506.
122. Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, et al. Recognition of HlA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004; 88: 29-41.
123. Manna PP, Jaramillo A, Majumder K, Campbell LG, Fleming TP, Dietz JR, et al. Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells. Breast Cancer Res Treat 2003; 79: 133-6.
124. Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst 2004; 96: 1388-96.
125. Tiriveedhi V, Sarma NJ, Subramanian V, Fleming TP, Gillanders WE, Mohanakumar T. Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen. Hum Immunol 2012; 73: 11-6.
126. Viehl CT, Frey DM, Phommaly C, Chen T, Fleming TP, Gillanders WE, et al. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. Breast Cancer Res Treat 2008; 109: 305-14.
127. Viehl CT, Tanaka Y, Chen T, Frey DM, Tran A, Fleming TP, et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res Treat 2005; 91: 271-8.
128. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004; 4: 531-42.
129. Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells. Mol Ther 2004; 10: 758-67.
130. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy. 2010; 2: 213-26.
131. Koh EH, Cho YW, Mun YJ, Ryu JH, Kim EJ, Choi DS, et al. Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells. Cancer Invest 2014; 32: 22-9.